May 07, 2025

Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer

In the phase III KEYNOTE-689 trial, perioperative use of a PD-1 inhibitor given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with ...

The ASCO Post

May 02, 2025

Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer

In the phase III KEYNOTE-689 trial, perioperative use of a PD-1 inhibitor given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with ...

The ASCO Post

April 21, 2025

Updated CAP Guideline Aims to Address Rising Rates of HPV-Associated Squamous Cell Carcinomas

The College of American Pathologists (CAP) updated its testing guideline to capture new research and emerging technologies to improve the diagnostic accuracy of human papillomavirus (HPV)-associated o...

The ASCO Post

April 16, 2025

Neoadjuvant Combination Immunotherapy for Head and Neck Cancer

A combination of two immunotherapies may improve treatment response among patients with head and neck squamous cell carcinomas compared with just one immunotherapy drug.

The ASCO Post

September 14, 2023

Pembrolizumab Plus Chemoradiation Therapy Falls Short in Locally Advanced Head and Neck Cancer

Pembrolizumab plus chemoradiation therapy failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation therapy alone in patients with locally advanced head an...

The ASCO Post

September 26, 2023

Personalized Biomarker-Based Umbrella Trial in Recurrent or Metastatic HNSCC

Learn more about the results of a personalized biomarker-driven umbrella trial for the treatment of patients with platinum-refractory recurrent and/or metastatic head and neck squamous cell carcinoma ...

The ASCO Post

September 14, 2023

Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer

In the phase III DARS study reported in The Lancet Oncology, Nutting et al found that dysphagia-optimized intensity-modulated radiotherapy (IMRT) was associated with improved patient-reported swallowi...

The ASCO Post

September 14, 2023

Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer

De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Resu...

The ASCO Post

March 05, 2024

HPV-Associated Oropharyngeal Cancer: Adjuvant Treatment Deintensification

Postoperative adjuvant therapy—both chemoradiotherapy and radiotherapy alone—for HPV-associated oropharyngeal squamous cell carcinoma may be safely de-escalated, according to results presented at the ...

The ASCO Post